��ɫ��

��ɫ��

Donate To Research Join The AAN

Events

Resources For

Abstract Details

Title Accurate Risk Assessment for the Development of PML in Natalizumab Treated MS Patients Requires CSF Analysis

Topic MS and Related Diseases

Presentation(s) (-)

Poster/Presentation
Number 056

Objective

Background

Design/Methods

Results

Conclusions

Authors/Disclosures
Margaret Bettin, MD	Dr. Bettin has nothing to disclose.
Jerry Lin, BS (Tisch Multiple Sclerosis Research Center of NY)	Mr. Lin has nothing to disclose.
Michelle M. Mielke, PhD (Wake Forest University School of Medicine)	Dr. Mielke has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Mielke has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai. Dr. Mielke has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly. Dr. Mielke has received personal compensation in the range of $500-$4,999 for serving as a Consultant for LabCorp. Dr. Mielke has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche. Dr. Mielke has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Siemens Healthineers. Dr. Mielke has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sunbird Bio. Dr. Mielke has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eisai. Dr. Mielke has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Roche. Dr. Mielke has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novo Nordisk.
Saud Sadiq, BS, FAAN (Tisch Multiple Sclerosis Research Center of New York)	Ms. Brewi has nothing to disclose.
	No disclosure on file